United States - English - NLM (National Library of Medicine)

grifols usa, llc - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h) - clostridium tetani toxoid antigen (formaldehyde inactivated) 2.0 [lf] in 0.5 ml - massbiologics' tdvax is a vaccine indicated for active immunization for the prevention of tetanus and diphtheria. this vaccine is approved for use in persons 7 years of age and older. a severe allergic reaction (e.g., anaphylaxis) occurring after a previous dose of this vaccine, or any other tetanus or diphtheria toxoid-containing vaccine, or any component of this vaccine is a contraindication to administration of massbiologics' tdvax vaccine. (see description ). because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with diphtheria or tetanus components should be carried out. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered.

Israel - English - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - suspension for injection - tetanus toxoid 5 lf / 1 doses; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses - diphtheria-pertussis-poliomyelitis-tetanus - active booster immunization against diphtheria, tetanus and pertussis in children, adolescents and adults aged 4 to 64 years. adacel is not indicated for treating diseases caused by b.pertussis, c.diphtheriae or c. tetani infections.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml; tetanus toxoid, quantity: 80 iu/ml; pertussis filamentous haemagglutinin, quantity: 50 microgram/ml; pertussis toxoid, quantity: 50 microgram/ml; diphtheria toxoid, quantity: 60 iu/ml; pertactin, quantity: 16 microgram/ml; poliovirus, quantity: 16 dagu; poliovirus, quantity: 64 dagu; poliovirus, quantity: 80 dagu - injection, suspension - excipient ingredients: aluminium phosphate; sodium chloride; aluminium hydroxide hydrate; neomycin sulfate; polymyxin b sulfate; water for injections; glucose monohydrate; ascorbic acid; polysorbate 80; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inositol; menadione; nicotinic acid; nicotinamide; aminobenzoic acid; pyridoxal hydrochloride; pyridoxine hydrochloride; riboflavine; thiamine hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium - infanrix hexa is indicated for primary immunisation of infants from the age of 6 weeks against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, and haemophilus influenzae type b. infanrix hexa is also indicated for use as booster dose if boosting with hepatitis b, poliomyelitis, and haemophilus influenzae type b, as well as diphtheria, tetanus and pertussis is required. refer to dosage and administration for further information.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria toxoid, adsorbed 2 [iu]; tetanus toxoid, adsorbed 20 [iu]; diphtheria toxoid, adsorbed 2 [iu]; tetanus toxoid, adsorbed 20 [iu] - solution for injection - active: diphtheria toxoid, adsorbed 2 [iu] tetanus toxoid, adsorbed 20 [iu] excipient: aluminium phosphate dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride thiomersal water for injection active: diphtheria toxoid, adsorbed 2 [iu] tetanus toxoid, adsorbed 20 [iu] excipient: aluminium phosphate dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride thiomersal water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria toxoid, adsorbed 60 iu/ml (30lf per dose of 0.5ml); tetanus toxoid, adsorbed 80 iu/ml (6lf per dose of 0.5ml) - solution for injection - >=(30, 40)iu/0.5ml - active: diphtheria toxoid, adsorbed 60 iu/ml (30lf per dose of 0.5ml) tetanus toxoid, adsorbed 80 iu/ml (6lf per dose of 0.5ml) excipient: aluminium phosphate dibasic sodium phosphate monobasic sodium phosphate dihydrate sodium chloride thiomersal water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria toxoid, adsorbed 12.5 lf u; tetanus toxoid, adsorbed 2.5 lf u - solution for injection - 12.5lf/2.5lf - active: diphtheria toxoid, adsorbed 12.5 lf u tetanus toxoid, adsorbed 2.5 lf u

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diphtheria toxoid, adsorbed 30 [iu]; tetanus toxoid 40 [iu] - solution for injection - active: diphtheria toxoid, adsorbed 30 [iu] tetanus toxoid 40 [iu] excipient: aluminium hydroxide sodium chloride thiomersal water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmabroker sales ltd - diphtheria toxoid, adsorbed 50 lf u/ml - solution for injection - 50 lf u/ml - active: diphtheria toxoid, adsorbed 50 lf u/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmabroker sales ltd - diphtheria toxoid, adsorbed 8 iu/ml; tetanus toxoid, adsorbed 80 iu/ml - solution for injection - >= 4,40iu/0.5ml - active: diphtheria toxoid, adsorbed 8 iu/ml tetanus toxoid, adsorbed 80 iu/ml excipient: aluminium phosphate sodium chloride thiomersal water for injection